Lack of association between genetic polymorphisms in cytokine genes and tumor recurrence in patients with hepatocellular carcinoma undergoing transplantation

Hepatobiliary and Pancreatic Diseases International

Volumn 12, Issue 1, 2013, Pages 54-59

  Wu, Li Ming ^a   Zhou, Lin ^a   Xu, Jun ^a   Wei, Ba Jin ^a   Cheng, Jun ^a   Xu, Xiao ^a   Xi, Bin ^a   Xie, Hai Yang ^a   Zheng, Shu Sen ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cytokine; Hepatocellular carcinoma; Polymorphism; Recurrence

Indexed keywords

CYCLOSPORIN A; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHINESE; DNA SEQUENCE; FEMALE; GENOTYPE; HETEROZYGOSITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84874255641     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(13)60006-5     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008;7:237-257.
3. Wu LM, Zhang F, Xie HY, Xu X, Chen QX, Yin SY, et al. MMP2 promoter polymorphism (C-1306T) and risk of recurrence in patients with hepatocellular carcinoma after transplantation. Clin Genet 2008;73:273-278.
4. Li XD, Wu LM, Xie HY, Xu X, Zhou L, Liang TB, et al. No association exists between E-cadherin gene polymorphism and tumor recurrence in patients with hepatocellular carcinoma after transplantation. Hepatobiliary Pancreat Dis Int 2007;6:254-258.
5. Li H, Xie HY, Zhou L, Wang WL, Liang TB, Zhang M, et al. Polymorphisms of CCL3L1/CCR5 genes and recurrence of hepatitis B in liver transplant recipients. Hepatobiliary Pancreat Dis Int 2011;10:593-598.
6. Howell WM, Rose-Zerilli MJ. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr 2007;137:194S-199S.
7. Alison MR, Nicholson LJ, Lin WR. Chronic inflammation and hepatocellular carcinoma. Recent Results Cancer Res 2011;185:135-148.
8. Ioana Braicu E, Mustea A, Toliat MR, Pirvulescu C, Könsgen D, Sun P, et al. Polymorphism of IL-1alpha, IL-1beta and IL-10 in patients with advanced ovarian cancer: results of a prospective study with 147 patients. Gynecol Oncol 2007;104:680-685.
9. Migita K, Maeda Y, Abiru S, Nakamura M, Komori A, Miyazoe S, et al. Polymorphisms of interleukin-1beta in Japanese patients with hepatitis B virus infection. J Hepatol 2007;46:381-386.
10. Heneghan MA, Johnson PJ, Clare M, Ho S, Harrison PM, Donaldson PT. Frequency and nature of cytokine gene polymorphisms in hepatocellular carcinoma in Hong Kong Chinese. Int J Gastrointest Cancer 2003;34:19-26.
11. Wang Y, Kato N, Hoshida Y, Otsuka M, Taniguchi H, Moriyama M, et al. UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma in japanese patients with hepatitis C virus infection. Clin Cancer Res 2004;10:2441-2446.
12. Migita K, Miyazoe S, Maeda Y, Daikoku M, Abiru S, Ueki T, et al. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection-association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol 2005;42:505-510.
13. Okamoto K, Ishida C, Ikebuchi Y, Mandai M, Mimura K, Murawaki Y, Yuasa I. The genotypes of IL-1 beta and MMP-3 are associated with the prognosis of HCV-related hepatocellular carcinoma. Intern Med 2010;49:887-895.
14. Snoussi K, Mahfoudh W, Bouaouina N, Ahmed SB, Helal AN, Chouchane L. Genetic variation in IL-8 associated with increased risk and poor prognosis of breast carcinoma. Hum Immunol 2006;67:13-21.
15. Kamali-Sarvestani E, Aliparasti MR, Atefi S. Association of interleukin-8 (IL-8 or CXCL8)-251T/A and CXCR2 +1208C/T gene polymorphisms with breast cancer. Neoplasma 2007; 54:484-489.
16. Jeng JE, Tsai JF, Chuang LY, Ho MS, Lin ZY, Hsieh MY, et al. Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia 2007;9:987-992.
17. Yu J, Zeng Z, Wang S, Tian L, Wu J, Xue L, et al. IL-1B-511 polymorphism is associated with increased risk of certain subtypes of gastric cancer in Chinese: a case-control study. Am J Gastroenterol 2010;105:557-564.
18. Bogunia-Kubik K, Mazur G, Wróbel T, Kuliczkowski K, Lange A. Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma. Tissue Antigens 2008;71:146-150.
19. Domingo-Domènech E, Benavente Y, González-Barca E, Montalban C, Gumà J, Bosch R, et al. Impact of interleukin-10 polymorphisms (-1082 and-3575) on the survival of patients with lymphoid neoplasms. Haematologica 2007;92:1475-1481.
20. Xie HY, Wang WL, Yao MY, Yu SF, Feng XN, Jin J, et al. Polymorphisms in cytokine genes and their association with acute rejection and recurrence of hepatitis B in Chinese liver transplant recipients. Arch Med Res 2008;39:420-428.
21. Wu LM, Xie HY, Zhou L, Yang Z, Zhang F, Zheng SS. A single nucleotide polymorphism in the vascular endothelial growth factor gene is associated with recurrence of hepatocellular carcinoma after transplantation. Arch Med Res 2009;40:565-570.
22. Hsia CY, Huo TI, Chiang SY, Lu MF, Sun CL, Wu JC, et al. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur J Surg Oncol 2007;33:208-212.
23. Chau GY, Wu CW, Lui WY, Chang TJ, Kao HL, Wu LH, et al. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 2000;231:552-558.
24. Wei YG, Liu F, Li B, Chen X, Ma Y, Yan LN, et al. Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility: a meta-analysis. World J Gastroenterol 2011;17:3941-3947.
25. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1-8.
26. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ. Lack of association between genetic polymorphisms in cytokine genes and disease expression in patients with hereditary non-polyposis colorectal cancer. Scand J Gastroenterol 2007;42:628-632.
27. Nahon P, Sutton A, Rufat P, Faisant C, Simon C, Barget N, et al. Lack of association of some chemokine system polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients with alcoholic cirrhosis: a prospective study. Eur J Gastroenterol Hepatol 2007;19:425-431.
28. Ognjanovic S, Yuan JM, Chaptman AK, Fan Y, Yu MC. Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. Carcinogenesis 2009;30:758-762.
29. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008;85:1726-1732.